← Leaderboards
Chaska Carlos Walton
Buck Institute For Research On Aging
$938,935
Attributed
$1,877,869
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $914.5K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,877,869 · 1
By mechanism
R01$1,877,869 · 1
Top collaborators
- Julie Kay Andersen3 shared
Most similar at Buck Institute For Research On Aging
Same institution · by research overlap
- Varghese John$11,000,502
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposAducanumabCellsAntibodiesAmericanAmino AcidsAmino Acid SequenceAmyloid Beta-ProteinCodeAnti-Inflammatory AgentsBiologicalBrainBrain RegionBudgetsAdvisory CommitteesCell TypeChimeric Antigen Receptor T CellsClinical TrialsAcademiaCombination Drug TherapyCombined Modality TherapyComplexCostAbeta Oligomer
Grant awards (3)
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures$914,477
R01 · FY2025 · AG
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures$476,782
R01 · FY2024 · AG
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures$486,610
R01 · FY2023 · AG